U.S. top court rejects Helsinn over anti-nausea drug patent in win for Teva

The nine justices unanimously upheld a lower court ruling that had canceled Helsinn’s patent on Aloxi for violating a provision in U.S. patent law that forbids sales of an invention before applying for a patent. Teva began selling its generic version of the drug in March 2018 after convincing the lower court to invalidate the patent. The high court’s decision comes after it previously refused Helsinn’s request to block the lower court ruling while it considered the company’s case, which allowed Israel-based Teva to bring its Aloxi generic to market.